Description:
Background: EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit), as one of
the polycyclic group proteins (PcGs), is an epigenetic regulator that plays a crucial role in the
pathophysiology of hematologic malignancies through regulating cell differentiation. Also, it
is well known that aberrant expression of specific transcription factors can be involved in the
pathogenesis of various cancers. Herein, we aimed to suppress EZH2 expression in MOLT-4
cells, T-ALL (T cell acute lymphoblastic leukemia) cell line, and evaluate the role of EZH2 on the
expression of transcription factors that regulate T cell maturation, differentiation, and apoptosis.
Methods: EZH2-siRNA was transfected into MOLT-4 cells, and the expression levels of
EZH2, NOTCH1, TCF1, IKZF1, and NFATC1 were measured using real-time PCR. The MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was performed to study
the effect of EZH2 knockdown on MOLT-4 cell viability. The apoptosis rate of EZH2-siRNA
transfected cells was assessed by flow cytometry. The interaction of mentioned genes was
investigated using STRING and GO (gene ontology).
Results: Our results have shown that EZH2-siRNA transfection can substantially decrease
EZH2 expression in MOLT-4 cells. Besides, EZH2 suppression can upregulate NOTCH1, TCF1,
IKZF1, and NFATC1 expression levels. EZH2 knockdown does not affect the viability and
apoptosis of MOLT-4 cells. The most remarkable protein-protein interaction of EZH2 has been
with NOTCH1. Besides, GO analysis has demonstrated that EZH2, NOTCH1, TCF1, IKZF1,
and NFATC1 were located within nucleoplasm and can regulate RNA polymerase II-mediated
transcription.
Conclusion: MOLT-4 cells harbor increased expression of EZH2 in comparison with normal
human T cells. EZH2 knockdown can upregulate the expression of the transcription factors
involved in T cell differentiation. Thus, EZH2 can halt the differentiation of immature
lymphoblastic T cells.
URL:
http://103.158.96.210:88/web_repository/uploads/ps-28-394.pdf
Type:
Journal
Document:
Diploma III Farmasi
Date:
23-06-2024
Author:
Sahar Safaei